1 – 15 of 31
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
(
- Contribution to journal › Article
- 2022
-
Mark
Mental health and psychosocial consequences linked to radiation emergencies - Increasingly recognised concerns
(
- Contribution to journal › Scientific review
-
Mark
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors : Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
(
- Contribution to journal › Article
- 2021
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2017
-
Mark
Kronisk myeloisk leukemi : förebild för målstyrd terapi - Revolutionerande överlevnadsvinster med definitiv bot i sikte och kraftigt förbättrad hälsoekonomi
(
- Contribution to journal › Article
-
Mark
Kronisk myeloisk leukemi : Förebild för målstyrd terapi
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia
(
- Contribution to journal › Article
-
Mark
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article
-
Mark
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
(
- Contribution to journal › Article